8-K/A: Aditxt Amends 8-K to Include Ignite Proteomics Financials

Aditxt, Inc. filed an amendment to its Form 8-K to provide the audited financial statements of Ignite Proteomics LLC and pro forma consolidated financial information following the acquisition.

Summary

• Aditxt, Inc. has filed an amendment (Form 8-K/A) to its previous Current Report on Form 8-K dated March 13, 2026.
• This amendment is to provide the required financial statements for the acquired business, Ignite Proteomics LLC, and the unaudited pro forma consolidated financial information.
• The acquisition of Ignite Proteomics LLC was completed on March 11, 2026.
• The filing includes audited financial statements for Ignite Proteomics LLC for the year ended December 31, 2025, and the period from May 30, 2024 (inception) to December 31, 2024.
• It also includes unaudited pro forma consolidated financial information for Aditxt, Inc. giving effect to the acquisition for the years ended December 31, 2025, and December 31, 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant financial losses and going concern issues of the acquired entity, Ignite Proteomics LLC, despite the completion of the acquisition.

Positives

• The filing provides necessary financial disclosures related to the acquisition of Ignite Proteomics LLC, fulfilling regulatory requirements.
• The pro forma financial information offers insight into the combined entity's potential financial position and performance.

Negatives

• Ignite Proteomics LLC incurred significant net losses in both 2025 ($5,701,059) and 2024 ($2,240,683).
• Ignite Proteomics LLC experienced a gross loss in 2025 ($358,524) and 2024 ($239,782).
• Ignite Proteomics LLC has substantial current liabilities ($7,064,320 as of Dec 31, 2025) significantly exceeding its current assets ($257,211 as of Dec 31, 2025).
• Ignite Proteomics LLC has a significant members deficit of ($6,807,109) as of December 31, 2025.
• The auditors' report for Ignite Proteomics LLC includes a statement of substantial doubt about the company's ability to continue as a going concern due to incurred losses and negative operating cash flow.

Risks

• Ignite Proteomics LLC has incurred losses and generated negative cash flow from operating activities, raising substantial doubt about its ability to continue as a going concern.
• The carrying amount of Ignite's laboratory equipment was $748,101, and an impairment loss of $748,101 was recognized in 2025 due to minimal cash flows generated from its use.
• The pro forma financial statements are preliminary and subject to change, particularly regarding the purchase price allocation and the valuation of intangible assets, which could materially impact future financial performance.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It primarily provides historical financial information and pro forma data related to a past acquisition. The future outlook of the combined entity will depend on the integration of Ignite Proteomics LLC and its operational performance.

Industry Context

StockSavvy.ai notes that the acquisition of specialized proteomics companies by larger entities is a trend driven by the increasing demand for advanced diagnostics and personalized medicine. However, the significant losses and going concern issues at Ignite Proteomics LLC highlight the high-risk, high-reward nature of early-stage biotechnology and diagnostics ventures.

Comparison to Industry Standards

• The net loss of Ignite Proteomics LLC ($5.7 million in 2025) is substantial for a company with only $43,539 in revenue, indicating a significant gap compared to established players in the diagnostics market like Quest Diagnostics or Labcorp, which operate at scale with profitability.
• The impairment of $748,101 on laboratory equipment due to minimal cash flows suggests operational inefficiencies or a lack of market traction for Ignite's specific technologies, contrasting with industry leaders who effectively leverage their assets.
• The pro forma consolidated net loss of Aditxt, Inc. ($48.9 million in 2025) indicates that the combined entity is still in a pre-profitability stage, a common characteristic of many biotech firms, but it is significantly higher than the revenue generated by the acquired entity.

Related Party Transactions

• Ignite Proteomics LLC had intercompany payables to its sole member, IMAC Holdings, Inc., totaling $4,578,815 as of December 31, 2025, and $1,744,595 as of December 31, 2024.
• The Member (IMAC Holdings, Inc.) contributed medical equipment and inventory valued at $1,043,862 and $90,771, respectively, as a capital contribution to Ignite Proteomics LLC.

Stakeholder Impact

• Shareholders of Aditxt, Inc. may see dilution if the Series A-2 Convertible Preferred Stock is converted, and the financial performance of the combined entity will impact their investment.
• Creditors of Ignite Proteomics LLC may face uncertainty regarding the settlement of its substantial liabilities, although Aditxt is expected to settle some operating liabilities post-acquisition.
• Employees of Ignite Proteomics LLC may experience changes in management and operational structure following the acquisition by Aditxt, Inc.

Next Steps

• Aditxt, Inc. will finalize the purchase price allocation for the acquisition of Ignite Proteomics LLC within one year of the closing date.
• The company will continue to integrate Ignite Proteomics LLC's operations.

Key Dates

Recommendation

The filing provides crucial financial details about the acquired entity, Ignite Proteomics LLC, revealing significant financial distress and going concern issues. While the acquisition itself is a strategic move, the immediate financial burden and integration challenges suggest a cautious 'hold' approach until Aditxt demonstrates a clear path to profitability and successful integration of Ignite's operations.

Keywords

Aditxt, 8-K/A, Ignite Proteomics, Acquisition, Financial Statements, Pro Forma, SEC Filing, Amendment